Skip to main content
Skip to main content


Name Investigator Tech ID Licensing Manager Name Micensing Manager Email Description Tags
Method to Elucidate Molecular Structure from Momentum Transfer Cross Section Christian Bleiholder 17-008 Matthieu Dumont <p>Ion mobility spectrometry-mass spectrometry (IMS-MS) is ideally suited to study co-existing, transient conformations of proteins and their complexes related to diseases because of its high sensitivity and speed of MS analysis.</p> <p>Many existing results suggest that IMS-MS could accurately elucidate structures for these protein conformations in a high-throughput manner.</p> <p>The present technology identifies how protein tertiary structures can be determined from IMS-MS data in an automated manner.</p> <h2>Advantages:</h2> <ul> <li>IMS-MS requires a fraction of sample amounts and time</li> <li>Does not suffer from charge-state dependent protein dynamics in the gas phase</li> <li>Computationally efficient</li> <li>Automatized</li> </ul> <p><span>Click here to watch an interview with Dr. Bleiholder: <span class="fa fa-caret-square-o-right"></span><span class="fa fa-blind"></span><span class="fa fa-check-circle"></span><span class="fa fa-hand-o-right"></span><a href=""></a></span></p>
Microfluidic Sample Preparation Device for Electron Microscopy Dr. Michael Roper and Dr. Scott Stagg 15-230 Dr. Matthieu Dumont <p>Cryogenic electron microscopy (cryoEM) is quickly becoming a routine method in the determination of high-resolution structures of biological molecules. However, for most samples before cryoEM data can be collected, the sample quality and heterogeneity must first be characterized using negative staining. Conventionally, EM grids are prepared by hand and, as such, variability is introduced due to user-to-user differences. The variability of the staining can have large effects on the final stained sample, ultimately hindering the resolution, image processing, and data analysis.</p> <p>A microfluidic platform is presented for preparing negatively stained grids for use in transmission electron microscopy (EM). The microfluidic device is composed of glass etched with readily fabricated features that facilitate the extraction of the grid post staining and maintains the integrity of the sample. The device allows for sealing of an electron microscopy grid, facile and reproducible delivery of a sample, followed by delivery of subsequent solutions that could be negative stains or other biological samples. The device houses the EM grid in an outlined chamber with an access point below the grid for gentle and easy recovery of the EM grid. The fluid is directed to the grid using the integrated channels of the microfluidic system.</p> <p>Utilization of this device simultaneously reduced environmental contamination on the grids and improved the homogeneity of the heavy metal stain needed to enhance visualization of biological specimens as compared to conventionally prepared EM grids.</p> <p>High-magnification images from grids prepared by the microfluidic system showed similar image qualities as those prepared by hand. With this methodology for housing the grid, opportunities are abound for more integrated systems using elastomeric materials for incorporation of valving and other microfluidic features. For example, this system can subsequently be complemented with gradient generators or multianalyte perfusion and reaction timers to study both multivariable interactions as well as reaction kinetics. This proof</p> <p>of principle paves the way for future added layers of complexity that can be used to uniquely investigate structural biology dynamics.</p> <h2>Advantages:</h2> <ul> <li>User friendly</li> <li>Reproducibility</li> <li>Parallel/high throughput</li> <li>Results have been published in Analytical Chemistry (Roper, 2016, American Chemical Society Publications) and led to multiple requests by research groups offering to beta test the prototype.</li> <li>Straightforward manufacturing</li> </ul> <p>For further reading, please visit:</p> <p><a href=""><strong></strong></a><strong> <br /></strong></p> <p><a href=""><strong></strong></a></p> <p><video alt="" width="400" controls="controls"> <source src="/media/4180/rs4-fin.mp4" type="video/mp4" /> Your browser does not support HTML5 video. </video></p>
Slip Mitigation Control for an Electric Powered Wheelchair Emmanuel Collins 14-060 Robby Freeborn-Scott <p>Electric Ground Vehicles (EGVs) such as electric automobiles, golf carts, and electric powered wheelchairs are increasing in use since they are energy efficient, environmentally friendly, and reduce oil dependency. However, when traveling across slippery surfaces, EGVs become susceptible to lateral slip.</p> <p>Our developed novel technology mitigates slip using feedback control. The essential components are the following: a reference model based on mass-damper system, a trajectory tracking controller for each wheel, and a maximum tractive force estimator. The reference model generates the desired acceleration, velocity, and position of the vehicle based on user inputs, for example, the position of the steering wheel and throttle or the commands from a joystick displacement. The user inputs are mapped to force and torque inputs to the reference model. The commanded trajectory is mapped to the desired wheel trajectories using the controller. The maximum tractive force estimator determines the minimum of the maximum tractive forces that can be applied to each wheel by the surface the wheel is traversing. An associated lower bound on the mass of the reference model is used to determine when one or more of the wheels has been required to follow a trajectory that requires more than the estimate of the min-max tractive force, such that it can be inferred that slip has occurred or may soon occur. Subsequently, the value of the mass parameter in the reference model is reduced to help ensure that future slip will not occur.</p>
A Novel Engineered Peptide for Treatment of Vascular Injury Ewa Bienkiewicz 16-110 Brent Edington <p>This technology uses an engineered peptide (A-OR2) to bind/neutralize hemin, reducing its toxic effects in living cells. A-OR2 is a modified version of peptide OR2 that binds hemin and reduces cell death in vivo. The A-OR2 peptide was engineered to adopt a more stable, B-like-structure, potentially resulting in a higher efficacy to neutralize toxic effects of hemin.</p> <p>This technology uses a modified version of the OR2 peptide to sequester/neutralize excess hemin and reduce the extent of injury. The OR2 peptide is a fragment of the prion protein that has been shown to be a part of the natural, protective response to stroke.</p> <p>Our preliminary data demonstrate that the hemin binding affinity for A-OR2 is higher than that for OR2. In addition, A-OR2 peptide is structurally more stable and folds faster.</p> <p>Overall, this technology employs a modified version of a peptide (OR2) that we have shown to reduce cytotoxic effects of excess hemin and alleviate vascular injury damage in a mouse model of hemorrhagic stroke.</p>
A Novel, Screening Assay for Colon and Rectum Cancer, based on a Antibody Specific for a Phosphorylated-Mcm2 at Serine 53 (Mcm2-S53P) Daniel Kaplan 16-093 Brent Edington <p>Approximately 4.5 percent of men and women will be diagnosed with colon and rectum cancer at some point during their lifetime, based on 2010-2012 data. The earlier colon and rectum cancer is caught, the better chance a person has of surviving five years after being diagnosed. Stool testing is likely to be particularly valuable, because it represents a non-invasive method for screening all of the colon and rectum, without the need for bowel preparation. The Mcm2 protein, a component of the DNA replication apparatus, is currently being developed for its use as an early marker of colorectal cancer in cells from stool washings. Mcm2 is a subunit of the replication fork helicase, the macromolecular assembly that unwinds DNA at a replication fork.</p> <p>Mcm2 lacks specificity because it is present in all stages of the cell cyle. The present invention identifies a novel post-translational modification of Mcm2, wherein the serine 53 residue is phosphorylated (Mcm2-S53P). This technology shows that the human Mcm2-S53P modification is an improved cancer marker compared to human Mcm2, and provides an improved screening array for cancer and other diseases of cell proliferation.</p> <h2>Advantages:</h2> <ul> <li>Higher sensitivity than other currently used markers of cell entry</li> </ul>
Monoclonal Antibodies Specific for 4,6-Diamino-5-(Formylamino) Pyrimidine Gary Ostrander and Eric Holmes 16-019 Brent Edington <p>The present invention describes monoclonal antibodies that are specific for 4,6-Diamino-5-(formylamino)pyrimidine. This structure, also known as FAPY-A, is formed in DNA bases by single electron oxidation reactions caused primarily by oxygen free radicals. Damage to DNA of this sort, along with its alternate product 8-hytdroxy-pyrimidine derivatives, can result in mutations from misreading if not first repaired. In the case of free radical oxidations of the DNA base Adenine, FAPY-A and 8-OH-A formed under more oxidative redox conditions. These different reaction products and their expression in biological tissues seem to correlate well with precancerous and cancerous changes in tissues. Thus, detection of FAPY-A and 8-OH-A via immunoassay may provide important future cancer risk information to individuals.</p>
Modified Fibroblast Growth Factor 1 (FGF-1) Polypeptides with Increased Binding Affinity for Heparin and Associated Methods Michael Blaber 15-039 Brent Edington <p>A Mutant FGF-1 was designed so as to increase the intrinsic affinity for heparin sulfate glycosaminoglycan; involving a point mutation that introduces a basic amino acid (i.e. Arg or Lys) at position Ser116. Characterization of this mutant (S116R) shows reduction in mitogenic stimulation, increase in growth factor receptor-1c activation, and prolonged duration of glucose lowering in hyperglycemic mice. Such a mutant form can be advantageous in reducing blood glucose and as a novel insulin sensitizer to treat metabolic disorder.   </p>
Selective Dopamine D4 Receptor Agonists for the Treatment of Working Memory Deficits Pradeep G. Bhide 14-038 Brent Edington <p>Dopamine is a critical regulator of working memory, a mechanism for short-term information storage. Deficits in working memory occur in diseases with dopamine imbalance such as ADHD, schizophrenia and Parkinson’s Disease. However, a targeted treatment for working memory deficits is not available. In rodent models with working memory deficits, we show that selective activation of the dopamine D4 receptor (D4R) improves working memory. Based on these findings we propose that drugs that selectively activate the D4 receptor are novel class drugs for the treatment for working memory deficits.</p> <p>D4R is found in abundance in the frontal cortex and hippocampus, brain regions that regulate working memory function. We examined two rodent models with working memory deficits, a prenatal nicotine exposure mouse model and the spontaneously hypertensive rat model. In both the models, activity and expression of the D$R are significantly decreased in the frontal cortex. Although dopamine D2 receptors expression and activity are also decreased in the frontal cortex of these models, improvements in working memory produced by psycho-stimulant administration were accompanied by increases in the activity of only the D$R and not the D2 receptor. Therefore, it can be concluded that selective increase in frontal cortical D4R activity is associated with improvement of deficient working memory.</p> <p>Dopaminergic drugs that activate or antagonize multiple dopaminergic receptors or that produce global increases in brain dopamine content have failed as effective treatments for working memory deficits because of their pleotropic actions. Our discovery suggests that drugs that selectively target the D4 receptor and improve its function are effective treatments for working memory deficits.</p>
TrkB Receptor Antagonist for Treatment of Cognitive Inflexibility Pradeep G. Bhide 15-137 Brent Edington <p>Cognitive flexibility is the ability to execute multiple mental tasks simultaneously, to switch from one task to the next easily, and to restructure knowledge and strategy to tackle changing tasks. Deficits in cognitive flexibility are associated with multiple psychiatric conditions including schizophrenia, autism spectrum disorder and ADHD. Despite its critical role in normal mental function, and despite its well documented associated impairment, drugs that selectively target and improve cognitive flexibility are not available.</p> <p>The present technology shows that excess brain derived growth factor (BDGF) is associated with deficits in cognitive flexibility and that ANA-12 is an effective treatment for cognitive ability.</p>
Novel Concept and Method for Developing and Screening ADHD Therapeutics Pradeep G. Bhide 15-138 Brent Edington <p>Attention Deficit Hyperactivity Disorder (ADHD) represents a conglomeration of multiple symptoms including inattention, hyperactivity, impulsivity and deficits in working memory. The proposed research shows that a prenatal nicotine exposure mouse model of ADHD displays each one of these symptoms, and that each symptom may have a distinct neurobiological basis. Moreover, the research using this mouse model suggests that improvement can be achieved in each symptom using a drug or a combination of drugs that selectively target specific neurobiological mechanism(s) underlying the symptom(s). However, at the present time, treatment for ADHD is not directed at tackling specific symptom domains or specific neurobiological mechanisms underlying such symptom domains. Development of drugs to target specific symptom domains or mechanisms is hampered by the lack of animal models that display the entire range of ADHD symptom domains, and in which each symptom domain and neurobiological mechanism can be assayed separately. Our mouse model of prenatal nicotine exposure fills this technological gap. Therefore, we advance the novel concept that drugs to selectively tackle each ADHD symptom domain can be screened using our mouse model. The significance of this concept is that efficacy of novel drugs can be evaluated against one or more specific ADHD symptom domains and their underlying neurobiological mechanisms.</p>
Comprehensive, Genome-Wide Epigenetic Fingerprinting by Replication Profiling David Gilbert 07-106 Brent Edington <p>This is a procedure for typing cells (cancer cells, stem cells, any kind of cells) based upon the order of replication of chromosome segments. In brief, cells from any source are pulse-labeled with 5-bromo-2deoxyuridine, sorted into early and late S-phase of the cell cycle by flow cytometry and the DNA replicated in each temporal compartment of S-phase is differentially labeled and hybridized to a DNA array consisting of evenly spaced probes from the entire genome. Using customized algorithms, the resulting data (ratio of each probe sequence replicated in early vs. late S-phase) can be converted into a form that can segment the genome and identify the order of replication of chromosome segments characteristic for a cell type. An alternative, if the cell line is difficult to label metabolically, is to sort cells into S-phase and G1-phase populations, hybridize differential labeled DNA from these sorted populations, and determine the ratio of each probe sequence in S vs G1. This provides similar data that can be evaluated by the same computational conversion.</p> <h2>Advantages:</h2> <ul> <li>More comprehensive (covers the entire genome)</li> <li>Less expensive (covers the entire genome for less than 1/20th what is needed for existing profiling methods)</li> <li>Much easier to interpret- the informative data for each cell line is distilled down to combinations of only about 1,000-2,000 segments of the genome that uniformly identify each cell type</li> <li>Measures very different properties of cells than any other method</li> <li>Focuses the analysis on the proliferating population of cells, which is particularly useful for stem cell and cancer technologies.</li> </ul>
A Reliable Assay for the Detection of Pork and Blood Components for Halal, Kosher, and Other Dietary Needs and Applications Yun-Hwa Hsieh 06-097, 12-194 Brent Edington <p>Nearly half of the world’s total population is strictly prohibited to consume pork and any substances derived from animal blood. However, food ingredients derived from pork and blood are widely used and present in various forms of dietary products without the awareness of consumers and even regulators.</p> <p>Analytical tools for monitoring these materials are lacking. Our laboratory at FSU possesses the only reliable technology to protect consumers who avoid eating products containing pork and blood, and such technology has been frequently sought for commercialization by a number of domestic and international companies for consumer protection in the markets of Kosher food for 13.8- million Jews; Halal foods for 1.6-billion Muslims; 1 billion of Hindus and non-religious vegans/vegetarians.</p> <p>The most desirable detection method is enzyme-linked immunosorbent assays (ELISA) which, coupled with our panel of monoclonal antibodies (mAbs) is able to detect protein ingredients derived from pork and blood components. These unique monoclonal antibodies are able to detect pork and blood from processed and cooked samples.</p>
Fibroblast Growth Factor (FGF) 1 with Mutation in the Heparin Binding Domain and Methods of Use to Reduce Blood Glucose Michael Blaber 15-211 Brent Edington <p>Type 2 diabietes and obesity are leading causes of mortality and are associated with the Western lifestyle, which is characterized by excessive nutritional intake and lack of exercise.</p> <p>The present technology provides mutated FGF1 proteins and methods of their use to reduce blood glucose and/or to treat a metabolic disease.</p>
A Peptide Building Block for P-trefoil Protein Architecture Dr. Blaber 10-114 Brent Edington <p>Protein folding is a poorly understood science, and therefore, protein engineering has yet to realize the functional potential inherent in proteins. Development of a useful "structural toolkit" for de novo protein design is a highly desirable, yet unrealized goal of the field.</p> <p>A novel 42 amino acid polypeptide sequence has been designed that spontaneously assembles into a homo-trimer, forming a thermostable P-trefoil protein architecture. The polypeptide can also be ligated, to form three identical repeating sequences within a single polypeptide, which also spontaneously folds into a thermostable P-trefoil protein architecture. The peptide is thus useful for either de novo design, rational design, or directed evolution of novel proteins based upon the P-trefoil architecture. The Invention represents an initial successful example of the development of a useful peptide building block for a common protein architecture (the P-trefoil).</p> <p>The peptide sequence was designed using a novel approach, and as a consequence there are an extremely limited number of useful related "building blocks" in protein design. The idea of a "structural toolkit" for protein design is largely conceptual; the current Invention is arguably one of the first successful examples.</p>
Bioreactor for Stem Cell Cultivation Teng Ma 03-001 Robby Freeborn-Scott <p>Maintaining adult stem cell lines is an important aspect of future research and development. The perfusion bioreactor mimics conditions encountered by adult stem cells within the human body by bathing stem cells in a protein-rich liquid and simulating the flow of the human body’s circulatory system. The reactor creates the ability to control what type of cells the stem cells become.</p> <p>The present technology enables automated seeding, harvesting, and transport, while sustaining high density human hematopoietic stem/progenitor cell expansion and RBC differentiation.</p> <h2>Advantages:</h2> <ul> <li>Allows for greater cell viability due to the lack of enzymatic treatment of the cells when harvesting</li> <li>Allows for significantly greater cell densities to be achieved than previously available technology</li> <li>Ability to direct differentiation and therefore control the type of cells ultimately produced</li> <li>Uses a “smart” coating that enables on-off affinity control between the cells and the scaffolds to achieve automated cell harvesting and transport. This feature eliminates the need for enzymatic treatment which simplifies large scale growth and increases the viable cell yield</li> <li>Modular design allows for the removal of individual flow chambers without interrupting the system. This is an attractive feature for research use where multiple samples are needed at various times</li> </ul>
Dual-Chamber Perfusion Bioreactor for Orthopedic Tissue Interfaces Teng Ma 10-013 Robby Freeborn-Scott <p>Adult mesenchymal stem cells (MSC's) have been used to regenerate bone and cartilage in both pre-clinical and clinical studies. This device can be used to fabricate from MSC's orthopedic interfaces such as bone-cartilage, ligament-bone, or muscle-tendon for implantation to correct orthopedic defects caused by disease or injury. The perfusion bioreactor chamber has two compartments connected by a porous scaffold for growing the tissue. The conditions such as substance concentration, pressure, and fluid flow rates can be individually controlled in each compartment and the pressure can be regulated so that the fluid can penetrate the scaffold transversely or horizontally. The porous scaffold supports cell growth and fluid penetration thereby providing the structure for the MSC's to form a functional tissue (bone, cartilage, etc.).</p> <p>Large tissue constructs require a controlled heterogeneous environment to grow properly. Previous bioreactor technology typically creates a homogeneous growth environment by introducing media flow in one direction and is not able to control the communication between different regions of the construct.</p> <h2>Advantages:</h2> <ul> <li>Able to control the biochemical and physiochemical conditions in each growth chamber individually </li> <li>Able to modulate the interactions and communication between two compartments by directing flow</li> <li>Enables the MSC's to differentiate two different cell types within the same construct; for example, chondrocytes and osteoblasts, thereby creating constructs composed of both cartilage and bone</li> </ul>
Mesenchymal Stem Cells (MSC) Expansion Teng Ma 11-054 Robby Freeborn-Scott <p>The present invention describes materials and methods for growing and expanding mammalian mesenchymal stem cells (MSC) while maintaining their undifferentiated phenotype, self-renewal ability, therapeutic potency, and/or multi-lineage potential. The method describes i) the seeding of freshly isolated MSC on a 3-D scaffold and their growth under physiological or low O2 tension for a period of time sufficient to support formation of 3-D extracellular matrix (ECM) network; ii) the decellularizing of the 3-D scaffold; and iii) the reseeding of the decellularized 3-D scaffold with MSCs, whereby the reseeded MSCs grow on the scaffold and maintain an undifferentiated phenotype. The 3-D scaffold comprises or is composed of poly(ethylene terephthalate) (PET).</p> <p>A faster production of highly potent human MSC is obtained using our methodology based on combining hypoxia and cell-derived ECM compared with the traditional culture methods utilizing growth factor supplements and a high concentration of serum.</p> <h2>Advantages:</h2> <ul> <li>Expands hMSC faster than the conventional methods</li> <li>Better presses hMSC's therapeutic potency compared with the traditional culture methods</li> <li>Requires a low concentration of serum and requires no exogenous factors to be added to expand the cells</li> </ul>
Method of Using RNA as an Inhibitor of HCV Dr. Hengli Tang 07-073 Brent Edington <p>The NIH estimates that four million Americans are infected with Hepatitis C Virus (HCV) and an estimated 8,000 to 10,000 Americans die annually of HCV related complications. This figure is expected to triple in the next 10 to 20 years. FSU researchers have utilized siRNA HT-161 to effectively block HCV replication and infection in cell culture. The replication is inhibited by clearing human cells of a protein essential for HCV replication. HT-161 inhibits diverse HCV strains including the genotype 1a and 1b that are prevalent and resistant to interferon therapy.</p> <p><a href="/media/3808/tang1_2.pdf" title="Tang1_2.pdf" data-id="6086">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>The method has been shown to prevent new infection and eliminates replicating HCV RNA from infected cells</li> <li>Can be utilized against a diverse selection of HCV</li> </ul> <h2>Advantages:</h2> <ul> <li>HT-161 targets a cellular gene necessary for viral replication thereby significantly reducing the likelihood of viral escape and resistance due to mutation</li> <li>Current therapies, such as interferon (IFN), have significant adverse side effects and HCV strains develop resistance to IFN treatment</li> <li>Unlike other siRNAs, the treatment does not target the viral genome, which, when targeted, increases the risk of mutations conveying resistances to treatment</li> </ul>
Reusable Colorimetric Fluoride Sensors Dr. Sourav Saha 10-186 Dr. Matthieu Dumont <p>Fluoridation of drinking water has been effective in preventing tooth decay and improving overall den-tal health; however, overexposure to fluoride poses numerous serious health risks including brittle bone disease and increases in bone cancers. Thus, accurate detection of fluoride levels in water and food sources as well as in body fluids is essential. </p> <p><a href="/media/4156/marketing-document-10-186-saha.pdf" target="_blank" title="Marketing document 10-186 Saha.pdf" data-id="7056">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>Medicine and health applications, both commercial and consumer-oriented, to test for the presence of fluoride in tap water, foods, blood and urine</li> <li>Food industry applications, such as testing toothpaste, bottled water, and food products</li> <li>Commercial product to enable water purifier manufacturers to test the effectiveness of their products more easily and at a reduced cost</li> <li>Municipal water-testing applications, particularly field testing</li> <li>Humanitarian application for use in developing countries with few or non-existent fluoride testing tools or standards</li> </ul> <h2>Advantages:</h2> <ul> <li>Offers both colorimetric and fluorimetric detection</li> <li>Can detect fluoride presence and quantity in a variety of environments including water, food, gas/air, and body fluids</li> <li>The sensors are easy to synthesize, environmentally benign, and can detect a range of fluoride concentration levels, with high sensitivity at extremely low nanomolar concentrations</li> <li>Dip-stick and spot-test forms are easy to use, effective, and comparatively inexpensive to produce</li> <li>Tests are reversible, reusable (with power source), and recyclable (disposable), thus reducing waste and costs</li> </ul>
Pulsed Gliding Arc Electrical Discharge Reactors Bruce Locke 06-142 Robby Freeborn-Scott <p>Gliding arc discharges have been investigated as a potential technology for gas phase pollution treatment and for liquid phase pollution treatment. Ultimately, the practical use of gliding arc technology to promote chemical transformations, such as the removal of organic pollutants in water or the generation of hydrogen peroxide, other reactive oxygen species, or reactive nitrogen species for treatment of potentially contaminated foods, depends on the efficiency that can be achieved.</p> <p>The present invention describes a plasma gliding arc discharge reactor that is useful for chemical transformations in liquids and gases. The reactor may include a housing having a plurality of divergent electrodes, a power supply connected to the electrodes delivering pulsed power to the reactor, and a nozzle that directs a mixture of a carrier gas and a liquid to a region between the divergent electrodes, thereby generating plasma in the region. The nozzle can include a first inlet for receiving the carrier gas, a second inlet for receiving the liquid and a mixing chamber that is configured to mix the carrier gas and the liquid prior to being directed to the region.</p>
Carbon Nanotube and Polymeric Thin Film Assemblies for Pressure Sensing and Mapping Dr. Liang, Dr. Lu, Dr, Whang and Dr. Zhang 08-132 Abby Queale <p>Pressure/force sensing technologies are used in a broad range of applications. Many pressure/force sensors are available, but thin film sensors are limited. Currently, the most common film pressure sensors are either resistive or capacitive, which are both reusable. This new technology utilizes the rupture of microcapsules filled with dyes for pressure sensing to create a disposable thin film mapping.</p> <p>The sensing assembly is composed of a top and bottom element. The top element is made of elastomer-like polymer with grooves that are filled with polymer gel electrolyte and the bottom is made of patterned conducting material thin film strips on top of flexible polymer film. When pressure is applied, a deformation of the material in the top element causes the gel to come in contact with the film strips, which creates an ionic-conducting path.</p> <p><a href="/media/3841/liu2.pdf" title="Liu2.pdf" data-id="6119">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>Seat occupancy detection in the automobile industry</li> <li>Tactile feedback for robots to sense and respond to environments</li> <li>Rehabilitation progress monitoring in the medical industry</li> <li>Bite force mapping in dentistry</li> <li>Measuring force of golf grips</li> </ul> <h2>Advantages:</h2> <ul> <li>Disposable</li> <li>Low percolation threshold</li> <li>Detects low levels of pressure sensing</li> <li>Utilizes ionic conduction as the major sensing mechanism</li> </ul>
Organic Chemical Synthesis using Plasma Reactors with Liquid Organic and Liquid Water Bruce Locke 13-153 Robby Freeborn-Scott <p>Electrical discharge plasma contacting liquid phases has been studied for a wide range of chemical, biomedical, environmental, and Materials synthesis applications.  The present invention utilizes a gas-water-organic plasma reactor for the conversion of alkanes into functionalized products (alcohols, aldehydes, etc.) using a pulsed plasma reactor with liquid water and flowing carrier gas. Hydrogen peroxide is also generated conjunction with the functionalized products.</p> <h1>Applications</h1> <ul> <li>Agriculture</li> <li>Healthcare</li> <li>Sanitization</li> <li>Waste water degradation</li> </ul>
A Novel Cell Culture System for Hepatitis C Virus (HCV) Dr. Tang 06-028 Brent Edington <p>This new culture system creates stem cell-derived human hepatocyte-like cells which are Hepatitis C Virus (HCV) infectable. This FSU-created technology establishes a new noncancerous and renewable cell culture system for HCV infection; enables direct infection by patient sera in vitro; identifies a defined transition to HCV permissiveness during hepatocyte differentiation; and demonstrates the feasibility of generating viral-resistant human hepatocyte-like cells in vitro.</p> <p>Primary human hepatocytes (PHHs) isolated from patient biopsies represent the most physiologically relevant cell culture model for hepatitis C virus (HCV) infection. However, these primary cells are not readily accessible, display individual variability, and are largely refractory to genetic manipulation. The  hepatocyte-like cells derived from stem cells not only overcomes these shortcomings but can also provide an unlimited source of non-cancer cells for both research and cell therapy. The system reports a novel infection model based upon differentiated human hepatocyte-like cells (DHHs) derived from stem cells, including human embryonic (hESCs) and induced pluripotent stem cells (iPSCs). Differentiated human hepatocyte-like cells (DHHs) derived from pluripotent stem cells have demonstrated hepatic functions but have not been explored for HCV infection studies as here. The ability to directly infect cultured cells with HCV patient serum, to study defined stages of viral permissiveness, and to produce genetically modified cells with desired phenotypes all have broad significance for host-pathogen interactions, drug resistance analysis and drug therapy.</p> <p><a href="/media/3986/tang4.pdf" title="tang4.pdf" data-id="6635">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>An HCV platform for drug-resistance analysis</li> <li>Infection studies and metabolic studies</li> </ul>
A Prosthetic Socket System with an Unprecedented Degree of Multifunctionality and Integration Dr. Zhang 12-160 Abby Queale <p>The proposed prosthetic Socket Optimized for Comfort with Advanced Technologies (SOCAT) integrate advanced materials, nanotechnology, electronics, and manufacturing technologies to achieve a prosthetic socket system with an unprecedented degree of multifunctionality and integration to meet the critical needs for advanced prostheses for patients. Despite the significant advances made in the past decade in the area of prosthetics, discomfort and adverse effects on the skin as a result of poor fit, elevated temperatures and moisture accumulation within the prosthetic socket are still a major problem.</p> <p>The proposed SOCAT invention utilizes four enabling technologies augmented with a product integration design to form a holistic above-knee socket system to resolve the issues mentioned above:</p> <ol> <li>Volume/shape change management will be realized with advanced materials that sense and respond to external stimuli, such as pressure changes due to either volume changes as a result of residual limb swelling or muscle tissue shape changes during a gait cycle</li> <li>Pistoning control and skin breakdown prevention will be realized via an innovative interface material embedded with nanoparticles</li> <li>Temperature and sweat control will be achieved by solid state active cooling using an array of miniature thermoelectric devices in combination with nanomaterials and phase change materials; and</li> <li>Lightweight piezoelectric nanofoam pressure sensors and printed electronic temperature and moisture sensors fully embedded in liners will provide the patient with an early warning of adverse situations, such as abnormal pressure suggesting improper gait or pistoning, and allow the practitioner to remotely collect real-time data for subsequent analysis.</li> </ol> <h2>Advantages:</h2> <ul> <li>Fully integrated product design that addresses major concerns of current sockets while minimizing parasitic parts and devices</li> <li>Lightweight, multifunctional material-enabled socket system</li> <li>Adaptive volume change management with coupled sensing/actuation materials</li> <li>Biomimetic materials for anti-microbial function and pistoning control</li> <li>Thermal management and perspiration control with solid state active cooling in conjunction with novel nanomaterials and phase changing materials</li> <li>Whole-field pressure monitoring by innovative lightweight piezoelectric materials</li> <li>Embedded printed electronics interconnects for sensing, wireless communication and local data storage</li> </ul>
Advancing Wound Treatment with Saloplastic Dressings Dr. Joseph Schlenoff 10-019 Dr. Matthieu Dumont <p>The demand for medical wound dressings is universal. Ranging in use from treating minor cuts to traumatic injuries, medical wound dressings prevent infections and save lives. In the case of traumatic injury, current wound dressings often require the application of a variety of materials, such as a combination of wound-filling gels, gauze, tape, and splints. However, Dr. Schlenoff’s research and discovery of saloplastics can decrease the number of necessary materials needed since saloplastic dressings can treat multiple aspects of a wound.</p> <p>The process of creating saloplastics uses salt instead of heat to melt plastics made from blends of charged polymers. By placing layers of positively and negatively charged electrolytes on top of one another, their electrical charges cancel each other out and create a neutrally charged, ultrathin film. These ultra-thin polymer coatings are useful for producing biocompatible surfaces that can be implanted into the human body for medical purposes.</p> <p>Approximately 750,000 Americans suffer strokes each year. Worldwide, that number increases to 20 million people. Primary stroke damage occurs from blood clotting and secondary damage occurs when toxic byproducts, including hemin, are produced from the trauma experienced during a stroke. This condition, known as hemin toxicity, leads to cell damage and cell death that in turn may cause irreparable brain damage or death for the individual.</p> <p>With Dr. Schlenoff’s research, stents used for implantation inside coronary arteries during surgical procedures could be coated with an ultrathin film that prevents cells and proteins from adhering, thus avoiding a narrowing of the arteries and restriction of blood flow.</p> <p><a href="/media/4155/marketing-document-polymer-schlenoff.pdf" target="_blank" title="Marketing document polymer schlenoff.pdf" data-id="7055">Download PDF version</a></p> <h2>Applications:</h2> <ul> <li>First responder scenarios</li> <li>Chronic Wounds</li> <li>Medical practitioners to consumers</li> <li>Military</li> </ul> <h2>Advantages:</h2> <ul> <li>Antibacterial, moldable when wet, and cast-like when dry</li> <li>Low heating temperatures, 45 – 55 degrees C, are needed to soften the material.</li> <li>One material can treat multiple aspects of a wound.</li> <li>Within minutes, the most serious wounds and breaks can be sealed and immobilized.</li> </ul>
Developing a High-Capacity Hemin Scavenger to Treat Stroke Victims Branko Stefanovic 12-047 Brent Edington <p>Fibrosis affects 45% of the population in the USA. It is characterized by excessive synthesis of type 1 collagen and scarring of various organs. This leads to organ insufficiency and death. The process is chronic and progressive and there are no approved drugs that can inhibit collagen synthesis. Aspects of the regulation of type 1 collagen production have been delineated and a drug screening procedure based on disruption of the regulatory pathway has been devised. Using this screening procedure a library of chemicals compounds has been screened and nine compounds that can inhibit collagen synthesis in cultured cells between 50-90% have been found.</p> <p>This is a completely novel approach to finding antifibrotic drugs. If these compounds prove to be effective in animal models and clinical trials, they will be the first chemicals that can directly inhibit collagen production. Since there is no cure for fibrosis, they may represent the first specific antifibrotic drugs.</p>
Identification of Major Cashew and Walnut Allergens Dr. Roux 01-029 and 12-155 Brent Edington <p>Cashews and walnuts are commonly used in snack foods and as an ingredient in a variety of processed foods, such as bakery and confectionary products. For those who are allergic to these nuts, consuming them can lead to reactions ranging from dermatitis to deadly anaphylactic shock. FSU researchers have identified specific amino acid sequences in walnut and cashew proteins that produce allergic reactions in humans.</p> <p>Researchers have identified allergens in cashews, walnuts, pecans, almonds, chestnuts, and pistachios using serum from allergic patients to screen cDNA expression libraries. Once cloned and expressed, the offending proteins are subjected to epitope mapping techniques and mutagenesis to generate a hypoallergenic version. At the same time, researchers are developing polyclonal and monoclonal antibodies to tree nut allergens to be used by the food industry in testing suspected foods for contamination with allergens.</p> <p><a href="/media/3988/roux2.pdf" title="roux2.pdf" data-id="6637">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>Test for cashew and walnut allergies</li> <li>Generate vaccines for patients with nut allergies</li> <li>Development of genetic modifications of the proteins in cashew and walnut plants to generate hypoallergenic plants</li> </ul> <h2>Advantages:</h2> <ul> <li>Previous methods use crude extracts for allergy testing and treatment</li> <li>Better defined reagents for testing and vaccination would reduce the risk of side effects</li> <li>Increase the reliability of allergy tests</li> <li>Hypoallergenic nuts would lessen health risk to allergy sufferers and reduce potential liability of food processors</li> </ul>
Immunoglobulin Peptides Against Heated Bovine Blood Dr. Hsieh 06-097 Brent Edington <p>Transmissible spongiform encephalopathy (TSE) agents induce fatal neurodegenerative diseases in mammalian species and humans. Bovine spongiform encephalopathy (BSE) in cattle, commonly known as mad cow disease, has brought enormous economic consequences since its first incidence in the United Kingdom in 1986. In addition, the emergence of a new variant form of Creutzfeldt-Jakob Disease (vCJD) in humans in the United Kingdom has been proposed to be possibly linked with BSE. Meat and bone meal, an ingredient of animal feed, contaminated with a TSE agent was believed to be the major vehicle of BSE transmission, according to epidemiological inquiry. To prevent the spread of BSE, the European Union in 1988 banned the inclusion of ruminant-derived proteins in animal feed. The U.S. Food and Drug Administration also introduced the feed ban in 1997 to prohibit the use of proteins derived from mammalian tissues in feeding ruminants</p> <p>Tools that permit enforcement of the meat and bone meal bans to eradicate BSE are becoming increasingly important for compliance with animal byproduct regulation. Furthermore, the accurate labeling of meat products is mandated and monitored by the United States Department of Agriculture (USDA) as well as by state and local governments.</p> <p>Among the various aspects of the present invention are immunoglobulin peptides which bind an antigen from bovine blood that may be used, for example, in a screening assay to identify or detect exogenous blood. The method comprises combining the sample with an immunoglobulin peptide which binds a thermostable antigen from bovine blood and determining whether any antigen from the sample was bound by the immunoglobulin peptide. This method can be used to determine the presence of bovine blood in a food sample or an animal feed sample.</p>
Novel Application of Melatonin Antagonists in Obstetrical Practice Dr. Olcese 08-058 Brent Edington <p>This is a method for the prevention of pre-term labor that will introduce, intravenously, a melatonin antagonist to women who are predisposed to premature birth. Melatonin antagonists are drugs that do not provoke a biological response themselves, but bind to melatonin receptors, and, therefore, prevent endogenous melatonin itself from binding to the receptor. It is believed that the inhibition of melatonin action will prevent women from beginning labor.</p> <p>Melatonin is a naturally occurring neurohormone found in most animals, including humans. Its role in the body is associated with the maintenance of a biological clock, or circadian rhythm. Besides this function, it is also a powerful antioxidant. Melatonin, or melatonin analogues, are consumed daily by millions of people for sleep induction. However, the application of melatonin in obstetrics represents a completely novel approach to the management of labor.</p> <p><a href="/media/3989/olcese2.pdf" title="olcese2.pdf" data-id="6638">Download PDF Version</a> </p> <h2>Applications:</h2> <ul> <li>Method for using melatonin to delay pre-term labor by targeting mothers who are at risk for premature labor.</li> </ul> <h2>Advantages:</h2> <ul> <li>Delay pre-term labor</li> <li>Save millions of dollars from premature births each year</li> <li>Prevent thousands of work hours for healthcare providers each year</li> <li>No expensive new drug development</li> </ul>
Novel Methods to Regulate Uterine Contractions Dr. Olcese 12-239 Brent Edington <p>The present invention describes a novel method of regulating uterine contractions in pregnant female using light. The method of regulating uterine contractions comprises suppressing a nocturnal endogenous melatonin level of a pregnant female experiencing uterine contractions by exposing the pregnant female during nighttime to a light source emitting visible light. Directing light from a light source positioned about 1 meter from the eyes, emitting predominantly blue light onto the pregnant females eyes between 9 p.m. to 6 a.m., with an intensity of about 10,000 lux of the visible light is sufficient to suppress the pregnant female's endogenous melatonin level.</p> <p>The results reveal that regular nocturnal contractions are suppressed by bright light exposure under these conditions. This finding supports the proposition that melatonin is a key zeitgeber, regulating the onset of human labor and parturition and that light can be used to regulate melatonin levels and, thereby, regulate uterine contractions. Optionally, the light source is adapted to emit light in discrete on/off cycles or pulses. The duration of the pulses and the separation between successive pulses is adjusted to obtain the desired amount of endogenous melatonin suppression.</p> <p>This invention will open new avenues for the management of term and preterm labor.</p>
Prophylactic and Post-acute use of Progesterone and its Enantiomer to Improve Outcomes Associated with Concussion Jacob Van Landingham 13-031 Brent Edington <p>The essential elements of this invention include: 1) nasal delivery of progesterone or its enantiomer for prophylactic use to improve outcomes associated with concussion, 2) the use of both compounds as molecular neuroprotectants and effective treatments post-acutely.</p> <p>An estimated 300,000 sports-related cases of Traumatic Brain Injury's (TBI), of mild (MTBI) to moderate severity, most of which can be classified as concussions, occur each year in the United States. The proportion of these concussions that are repeat injuries is unknown; however, there is an increased risk for subsequent TBI among persons who have had at least one previous TBI. Brain injury causes Lesions that appear and change over time in the prefrontal cortex and its pathways to the older regions of the brain. This can result in the wide spectrum of complex neurobehavioral complaints following MTBI: compulsive and explosive behavior, sensory anomalies, memory loss, as well as behavioral dis-inhibition, domestic violence, and alcohol intolerance. Worse, repetitive head injuries, even minor ones, can have serious repercussions including permanent brain damage or death.</p> <p>Due to the lack of a consistent definition, the economic costs of MTBI are not known, but they are estimated to be very high ($5 billion). These high costs are due in part to the large percentage of hospital admissions for head injury that are due to mild head trauma, however, indirect costs such as lost work time and early retirement account for the bulk of the costs. These direct and indirect costs cause the expense of mild brain trauma to rival that of moderate and severe head injuries.</p> <p>A 1999 study of college football players found that their learning disorders and reduced neuropsychological performance were independently associated with multiple concussions. Verbal learning and memory appeared to be the most sensitive components in athletes with concussions. A survey of retired professional football players found that 60% had suffered at least one concussion during their careers, and 26% reported three or more concussions. Significantly fewer neurological symptoms were reported from players who had no concussions.</p> <p>A growing body of data suggests that those who suffer repetitive head injuries in sports may be at a greater risk for neurodegenerative diseases later in life. The cumulative damage from successive concussions can increase the risk of premature senility, Alzheimer's disease, and Parkinson's disease.</p>
Use of D-serine as an Antagonist of Triheteromeric N-methyl-0-aspartate Receptors Sanjay Kumar 13-144 Brent Edington <p>D-serine, the D-stereoisomer of serine, synthesized in the brain by serine racemase from its L-stereoisomer is considered a co-agonist I co-activator of glutamatergic N-methyl-0-aspartate receptors (NMDARs). However, this action of D-serine seems exclusive to di-heteromeric NMOARs containing subunits GluN1 and GluN2.</p> <p>We have determined that D-serine works as a potent antagonist I inhibitor of GluN3-containing triheteromeric NMDARs that were discovered in our laboratory recently and found to exist in various regions of the brain. The discovery of this seemingly opposite effect on NMDARS has many therapeutic and non-therapeutic advantages including, but not restricted to, the following:</p> <p>1. D-serine, unlike other NMOAR antagonists,may be well-tolerated in the brain, because it is naturally synthesized in the brain</p> <p>2. D-serine's effect seems to be subunit specific (affecting only NMDARs that contain GluN3A or GluN3B whether they be di- or triheteromeric) making it amenable for targeted therapeutics (not all NMDARs would be affected by it in this way)</p> <p>3. D-serine's antagonism of GluN3-containing triheteromeric NMDARs may be important because these receptors appear significantly more permeable 1 selective for calcium, a potent excitotoxicant that underlies cell death under a number of scenarios including epilepsy. Hence blocking these receptors specifically may aid in averting underlying pathology</p> <p>4. D-serine can be used as a tool in basic research for identifying the expression of and determining the location of GluN3-containing triheteromeric NMDARs in the brain </p>
Polyethylene Glycol Based Oligomers for Coating Nanoparticles Dr. Hedi Mattoussi 12-026 Dr. Matthieu Dumont <p id="p-0013" class="style-scope patent-text">We have developed nanoparticle coatings that are water dispersible, have a strong affinity for binding to magnetic nanoparticles, and can be easily modified for attaching the coating to biological materials. The nanoparticle coatings comprise a polyacrylic acid based backbone onto which PEG-based oligomers are appended by modifying the native carboxyl groups of the PAA backbone. The PEG-based oligomers include functional groups on their terminal ends, which are chosen to provide a certain function. Some of the terminal functional groups bind the coatings to the nanoparticle's surface, while others provide reactive sites for binding other compounds to the coating. The method we developed for making these coatings allows one to tune the number and type of PEG-based oligomers appended to the PAA backbone based on the desired properties of the coating.</p> <p id="p-0014" class="style-scope patent-text">In accordance with a composition aspect of the invention, the nanoparticle coatings comprise repeating polyacrylic acid monomers covalently bound together in an aliphatic chain having a plurality of carboxylic acid functional groups and modified carboxylic acid functional groups extending there from. A first portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having a terminal methoxy functional group and a second portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having at least one terminal catechol group.</p>
Thiol-ene polymer metal oxide nanoparticle high refractive index composites Dr. Albert Stiegman 12-228 Dr. Matthieu Dumont <p>For optical applications in general and eyewear in particular, the synthesis of new polymers with refractive indices &gt;1.65 and acceptable Abbe numbers is of considerable importance. Higher refractive index materials will permit smaller, lighter weight lenses to be used and provide a much broader graded index for progressive lenses. The material modification that leads to higher refractive indices is the incorporation of highly polarizable atoms and ions. Incorporating such polarizable groups has been the standard protocol used to develop new high R.I. polymers. The electronic polarizability is a tensor property of an atom or molecule that measures the distortion of the electron cloud in the presence of an applied electric field (which can be an optical field). The more the electron cloud can be distorted, the higher the refractive index. The characteristics of atomic and molecular electronic structure that yield large polarizabilities are well understood and can be predicted from basic chemical principles. In particular, the more electronegative an atom is the less polarizable it will be, hence late first-row elements such as F, O and N tend to yield lower refractive index materials. Better choices are 2<sup class="style-scope patent-text">nd</sup>, 3<sup class="style-scope patent-text">rd </sup>or 4<sup class="style-scope patent-text">th </sup>row main group elements such as S (which is currently used in order to increase the refractive index in many polymeric materials), P, and Sn. From a molecular standpoint, the higher electronegativity of the first row can be overcome by delocalization of the electrons across several atoms. Aromatics are more polarizable than saturated hydrocarbons and compounds such as propylene carbonate and dimethylformamide have high dielectric constants.</p> <p>the present invention comprises a bulk polymer composite comprising a thiol-ene polymer matrix, or a matrix comprising a corresponding polymer derived from a phosphinyl, selenol, or arsinyl monomer, and metal oxide nanoparticles dispersed within the matrix, said nanoparticles being bonded to polymer molecules contained in the matrix. In certain preferred embodiments, the polymer matrix comprises a matrix corresponding to the structure.</p>
Tumor Drug Resistance Measured by Sodium Diffusion Dr. Schepkin 12-106 Abby Queale <p>This invention is a non-invasive, comprehensive and individualized evaluation of tumor resistance using sodium and/or diffusion magnetic resonance imaging (MRI). The method includes conducting a sodium and/or diffusion MRI on a tumor of a subject and on a normal region of the subject- for example, the normal region in brain being contralateral to the tumor. When the images of the MRI procedures have been obtained, the indicias (i.e., sodium and/or diffusion) are measured and analyzed. These indicias are compared between the tumor region and normal region. A low level of the indicia in the tumor region, relative to the level of indicia in the normal region, indicates a higher/increased tumor resistance to a drug.</p> <p>Currently, a biopsy and Positron emission tomography (PET) are the conventional technologies used to deliver information on tumor resistance prior to therapy. The evaluation can be performed prior to therapy and can help select a strategy of treatment but also help in evaluating the efficacy of an agent for the treatment of cancer in a subject. The invention can be used in the brain glioma model but is contemplated for use in different types of tumors in most parts of the human body in addition the agent may be carmustine, though other tumor types and agents are contemplated by the invention. The level of tumor resistance can be determined reproducibly in a relatively short amount of time, for example less than thirty minutes, and the results can be used immediately to create individualized therapy.</p> <p>The invention allows clinicians to avoid ineffective therapies, which may be more harmful than useful or come up with the other more appropriate alternatives. It can facilitate a separation of the effects due to metabolic changes in the tumor at the beginning of therapy from the effects introduced by drug intervention.</p>
Genome Capture and Sequencing to Comprehensively Map Chromatin Structure in Complex Genomes Dr. Jonathan Dennis 14-044 Brent Edington <p>This invention brings significant improvement to our ability to query the chromatin structure of select important regions of the entire human genome. Utilizing a unique sequencing strategy, the invention offers a solution-based sequence capture method enabling the enrichment of the 2000 bp surrounding the transcription start site of 25,464 human open reading frames. This enrichment reduces the sequence space of the human genome from 3.4 Gb in total to 50 Mb of transcription start sites, a 98.5% reduction. Additionally, the enrichment is analogous to that achieved for well-documented exome sequencing experiments. This sequence capture approach will allow researchers to multiplex chromatin structure analyses in Illumina HiSeq2500 lanes, thereby opening this strategy for a wide range of diagnostic and prognostic indicators in human disease.</p> <h2>Applications:</h2> <ul> <li>Identify stages in the progression of cancer</li> <li>Identify host response in viral infection (HIV and KSHV)</li> <li>Define cryptic effects of drugs of abuse (amphetamines, cocaine, and nicotine)</li> </ul> <h2>Advantages:</h2> <ul> <li><span>Allows for the targeted analysis of specific areas of interest in complex genomes</span></li> <li><span>Provides a cost effective strategy for querying multiple samples in a single reaction</span></li> <li><span>Provides an extremely cost effective way to screen patient samples </span></li> <li><span>Opens a new field of biomarker development: distribution of nucleosomes</span></li> <li><span>Nucleosome distribution mapping is independent of genotype and gene expression</span></li> </ul>
Detecting Interaction of CFTR Polypeptides Dr. Teem 08-009 Brent Edington <p>Cystic fibrosis (CF) is the most common genetic disease of Caucasians in North America, occurring at a frequency of approximately 1 in 2500 births. The disease results from defective function of the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein in a variety of tissues, including the pancreas and the lung epithelium.</p> <p>The present invention describes materials and methods for detecting the interaction of CFTR proteins. The method can be used to determine whether one CFTR NBD1 polypeptide interacts with a second CFTR NBD1 polypeptide using a yeast dual hybrid assay. The subject methods can be used to determine whether mutations to the CFTR polypeptide reduce or eliminate dimerization of the CFTR polypeptides. The present methods can also be used to screen and identify revertant mutations that restore dimerization of a mutant CFTR polypeptide, as well as mutations that enhance dimerization and CFTR activity greater than that of wildtype protein.The subject invention also provides materials and methods for efficiently identifying and screening for compounds, drugs and other such compositions that facilitate proper dimerization of the CFTR polypeptides and would be candidate agents for use in treating patients having CF. </p> <h2>Advantages:</h2> <ul> <li>The use of a yeast growth bioassay is fast and inexpensive in comparison to current screening procedures that involve mammalian cells and assays for CFTR channel activity</li> <li>Can be used to evaluate a large number of compounds in a high throughput format</li> </ul>
Quantitative Analysis of Metabolic Mixtures by 2D 13C-Constant-Time TOCSY NMR Spectroscopy Rafael Bruschweiler 13-204 Matthieu Dumont <p>Quantification of metabolite concentrations is a key task in metabolomics studies.</p> <p>Significant peak overlaps in 1D NMR spectra of metabolomics samples prevent straightforward quantification through 1D peak integrals.Using uniformly 13C-labeled organisms, the 2D NMR 13C-13C constant-time (CT) TOCSY experiment provides high-resolution information about individual metabolites that allows their identification via database searching or, in the case of novel compounds, through the reconstruction of their backbone-carbon topology.</p> <p>FSU researchers demonstrated how CT-TOCSY spectra can also be utilized for quantification purposes. The methods are demonstrated for carbohydrate and amino-acid mixtures.</p>
Homeless Shelter Infant Cradle Dr. Pable 08-168 Abby Queale <p>The present invention describes a cradle designed to be used for infants of families who reside in homeless shelters. This cradle design solves the problem of homeless families nurturing their infants in bed which creates a smothering hazard. The cradle, used in the context of an extremely small bedroom, has a unique construction that permits it to be pulled up close alongside the bed and allows the infant to be nurtured while the caregiver is in bed. Many shelters utilize prison-style beds with a unique under-bed storage unit that this work accommodates, allowing the cradle to be placed directly alongside the bed.</p> <p>The cradle's third prototype has been completed and the cradle has been placed in its end location (a local homeless shelter) that enabled a check for suitable dimensions and weight.This furniture object potentially represents a small, but potentially lifesaving improvement to homeless shelter family living dormitories.</p> <h2>Applications:</h2> <ul> <li>The potential scope of its use is vast, with the Department of Housing and Urban Development reporting 95,000 family beds in homeless shelters and an additional 3,000 family beds in transitional shelters nationwide (The 2nd Annual Homeless Report to Congress, March 2008).</li> </ul> <p> </p>
Method of Treating Multiple Sclerosis with Anti-K6 Antibody Michael Blaber 03-013 Brent Edington <p>This invention is based on the discovery that modulators of kallikrein 6 can alter pathogenesis of inflammatory cell mediated diseases both within the central nervous system and in the periphery. As a result, modulators of kallikrein 6 can aid in the treatment and prevention of inflammatory conditions such as MS, rheumatoid arthritis, lupus, and asthma. An antibody having specific binding affinity for kallikrein 6 reduced the degree of demyelination and reduced behavioral defects in animal models of multiple sclerosis.</p> multiple sclerosis,,rheumatoid arthritis,lupus,and asthma
Computer Software that Reduces Known Risk Factors for Anxiety, Depression, and Related Issues Dr. Norman B. Schmidt 15-175 Dr. Matthieu Dumont <p>According to the World Health Organization anxiety and related issues, including addictions and mood problems as well as suicide, represent some of the most prevalent and disabling conditions across all physical and mental health disorders. As such, there is a clear public health need to more effectively prevent, mitigate and treat these issues.</p> <p>Despite their prevalence and impairing nature, many of these problems respond remarkably well to treatment. It sounds almost too good to be true, but decades long conditions can be effectively removed in a few weeks with proper treatment. Our computer delivered interventions are even briefer – only about 50 minutes long. Despite their brevity, we have found that these interventions have considerable and long lasting positive benefits. Specifically, these brief treatments reduce the targeted risk factor by about 30% and these reductions are durable for as long as two years. Currently, we have two computer interventions - one focuses on stress sensitivity and the other on social isolation. These constructs have a considerable empirical foundation and are implicated as critical mechanisms involved in anxiety and mood problems.</p> <p>Our work in this area combines three key tasks: (1) identification of malleable risk factors, (2) developing interventions for these risk factors, and (3) using technology to facilitate delivery of the interventions.</p> <p>Technology is increasingly used to assist medical professionals. In regard to risk factors, our approach has been to develop interactive computer programs that guide participants through the information and skills needed to correct the problem of interest. These computer programs are brief (under one hour) and are readily disseminated via the web.</p> <p><a href="" target="_blank">More on Dr. Schmidt</a></p> <p> </p>
Materials and Methods for Cryopreserved Bone Contstructs Teng Ma 11-011 Robby Freeborn-Scott <p>The technology developed includes materials and methods for cryo-preservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused with a suitable cryo-preservation fluid transversely across the HCG-cell constructs in the bioreactor. The cryo-preservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e. g., fetal bovine serum (FBS)). In one embodiment, the HCG-cell constructs are perfused for a suitable period of time with cryo-preservant fluid using transverse flow of the fluid in the bioreactor at a suitable flow rate. The HCG-cell constructs (or the perfusion chambers containing them) are then removed from the bioreactor and placed in a cryo-preservant media and maintained at increasingly colder temperatures until temperatures reach about  -80° C. The frozen HCG-cell constructs (or the chambers containing them) can then be stored at a suitable cryogenic temperature (e.g., in liquid nitrogen) until needed. When needed, frozen HCG-cell constructs can be removed from cold storage and thawed using suitable means (e. g., 37°C. water bath). Cells contemplated for use in the presentinvention include stem cells, such mesenchymal stem cells.Cells can be animal cells, such as mammalian cells or human cells.</p>
Central Executive Training for ADHD Dr. Michael Kofler 16-106 Dr. Matthieu Dumont <p>Attention-deficit/hyperactivity disorder (ADHD) is a complex, chronic, and potentially debilitating disorder of brain, behavior, and development that affects approximately 5.4% of school-aged children at an annual U.S. cost of illness of over $42 billion. Medication and behavioral treatment are effective for reducing symptoms, but they are considered maintenance therapies because their benefits disappear within minutes to hours after treatment is stopped. Clearly, novel treatments are needed.</p> <p> </p> <p>Central Executive Training (CET) is a novel, evidence-informed, computerized training protocol developed based on recent advancements in clinical and neuropsychological science. It differs fundamentally from existing, capacity-based “working memory training” programs. Each of CET’s 9 training games implement advanced algorithms to adapt based on the child’s performance and build capabilities across three, empirically-identified functions of the midlateral prefrontal cortex. These 3 functions involve dual-processing, continuous updating, and temporal ordering, and are collectively known as the brain’s ‘central executive.’</p> <p> </p> <p>Central executive abilities are targeted in CET based on fMRI evidence of significant cortical underdevelopment in these areas in children with ADHD. Importantly, our previous work has shown that hyperactivity and inattentive symptoms are most pronounced in children with ADHD when they are engaged in activities that challenge their underdeveloped central executive abilities. In fact, several studies have found that children with ADHD do not show attention deficits or hyperactivity during conditions with minimal central executive demands.</p> <p> </p> <p>Our preliminary data show that CET is superior to the current gold standard psychosocial treatment (behavioral parent training) for improving working memory in children with ADHD. Our data also show that CET is superior to the gold standard for reducing hyperactivity symptoms measured using high-precision actigraphs that sample children’s movement 16 times per second. CET was equivalent to the current gold standard for reducing ADHD symptoms based on parent report. A randomized clinical trial of CET is underway.</p> ADHD
Mutations of the Rhodopsin Gene in Zebrafish and uses of the Mutations James Fadool 17-038 Brent Edington <p>The invention involves isolation and use of zebrafish having novel genetic mutations in the rhodopsin genes dealing with retinal disease to serve as a model for human retinal disease. Rhodopsin is a protein receptor expressed in the light sensitive cells of the retina responsible for initiation of vision. Nearly 100 spontaneous mutations in the human rhodopsin genes are associated with inherited photoreceptor degeneration, retinitis pigmentosa, progressive retinal degeneration, low vision and blindness for which there are currently no cures. The novel zebrafish models were generated to produce known disease causing mutations in the zebrafish rhodopsin genes. DNA sequencing revealed the novelty of the isolated zebrafish mutations. Analysis of the retinal phenotypes associated with the novel alleles of zebrafish rhodopsin genes revealed that specific mutations were associated with phenotypes that mimic photoreceptor defects and degeneration observed in humans. These zebrafish models provide novel tools for investigating the cellular consequences of expression of mutated forms of rhodopsin, and are useful for genetic, small molecule, and chemical screens, or molecular manipulations with the goal of discovering compounds, genes, or treatments that may alter, slow, reverse or prevent the photoreceptor defects.  </p>